Kamat Ashish M, Lobo Niyati, Lerner Seth P, Li Roger, Matulay Justin T, Palou Joan, Witjes J Alfred, Rouprêt Morgan, Smith Angela B, Chang Sam S, Shore Neal D, Steinberg Gary D, Dinney Colin P, Svatek Robert S, Lamm Donald L
Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA.
Bladder Cancer. 2022 Jun 3;8(2):113-117. doi: 10.3233/BLC-211648. eCollection 2022.
When it comes to the treatment of patients with non-muscle-invasive bladder cancer (NMIBC) with intravesical bacillus Calmette-Guérin (BCG), two questions must be considered: 1) what dose to give, and 2) for how long? The issue of optimal dose and duration has been the subject of several randomized trials and is especially pertinent in the context of a global BCG shortage. Despite this, there appears to be uncertainty as to whether BCG dose or duration may be compromised in the event of shortage. As such, we wish to summarize the available evidence as an aid to the practicing urologist.
在使用膀胱内卡介苗（BCG）治疗非肌肉浸润性膀胱癌（NMIBC）患者时，必须考虑两个问题：1）给予何种剂量，以及2）持续多长时间？最佳剂量和疗程的问题一直是多项随机试验的主题，在全球卡介苗短缺的背景下尤为相关。尽管如此，在短缺情况下卡介苗剂量或疗程是否可以折衷仍存在不确定性。因此，我们希望总结现有证据，以帮助执业泌尿科医生。
